Catalyst Wire Dossier Catalyst Wire Dossier

Incruse Ellipta (umeclidinium bromide)

umeclidinium bromide · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Incruse Ellipta (umeclidinium bromide), covering 2014-11-25 to 2014-11-25. Get the full timeline:

Most recent: Clinical Trial Update: Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

See pricing